Epidemiology of ovarian cancer in Assiut Governorate, Egypt
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20184510Keywords:
Epidemiology, Ovarian cancer, Ovarian malignancy, SurvivalAbstract
Background: The aim of this study is to assess ovarian cancer epidemiology and detect its prognostic factors in Assuit, Egypt.
Methods: This retrospective study was performed between January 2010 and December 2015, on all cases attending to Obstetrics and Gynecology Outpatient Clinic in all central hospitals in Assiut. 378 females (≥40 years old) came to Obstetrics and Gynecology Outpatient Clinic from January 2010 to December 2015. Inclusion criteria: All females (≥40 years old), history of current acute or chronic pelvic pain, mass; fixed, hard consistency, history of previous similar condition.
Results: Mean age for whole ovarian cancer cases in this study was 56.44±10.08 (range, 40-85). Nulliparity was found in one case (0.3%), while multiparity was found in 252 cases (66.7%). Grand multiparity was found in 113 cases (29.9%). Twelve cases (3.2%) were virgin. Vaginal ultrasound can find all ovarian cancer cases. Regarding the serum levels of the tumor biomarker, CA-125, the average level of CA-125 is 300-1000 U/ml with 34.9% of cases had readings below to 300-1000 U/ml and 6.1% of cases had readings above to this average level. Regarding treatment, treatment combining surgery with chemotherapy was the main line of management in present study (46.3%). About 33.3% of cases underwent surgery, while only 18.3% took the chance of chemotherapy. Eight cases (2.1%) had no treatment.
Conclusions: Epithelial ovarian cancer is a lethal disease. The age incidence of ovarian cancer in present patients is ten years younger than what is re¬ported in US SEER data and other Western countries. CA-125 level and ultrasonography are increasing the rate of suspicious for diagnosis of malignant tumors.
Metrics
References
Ahmedin Jemal DV, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics, 2004. CA A Cancer J Clin. 2004:8-29.
Ibrahim AS, Seif-Eldin IA, Ismail K, Hablas A, Hussein H, Elhamzawy H. Cancer in Egypt, Gharbiah: Triennial Report of 2000-2002, Gharbiah Population-based Cancer Registry. Cairo: Middle East Cancer Consortium. 2007.
Egypt National Cancer Registry, Aswan Profile: Ministry of Communication and Information Technology. 2008.
Harries M, Gore M. Part I: chemotherapy for epithelial ovarian cancer–treatment at first diagnosis. Lancet Oncol. 2002;3(9):529-36.
Chi DS, Zivanovic O, Palayekar MJ, Eisenhauer EL, Abu-Rustum NR, Sonoda Y, et al. A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma. Gynecol Oncol. 2009;112(1):6-10.
Mostafa MF, El-etreby N, Awad N. Retrospective analysis evaluating ovarian cancer cases presented at the Clinical Oncology Department, Alexandria University. Alexandria J Med. 2012;48:353-60.
Tekay A, Jouppila P. Controversies in assessment of ovarian tumors with transvaginal color Doppler ultrasound. Actu Obstet Gynecol Scand. 1995;75:316-29.
Hegazi RA, Wahab KA, Nahas WE, Mosbah M, Refky B. Epidemiological and pathological correlates of postoperative mortality of patients with ovarian cancer. Surgery Curr Res. 2013;3(126):2161-76.
Alsop K, Fereday S, Meldrum C. BRCA mutation frequency and patterns of treatment response in BRCA mutation–positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30(21):2654-63.
Elattar I. Cancer in the Arab World: Magnitude of the problem. In The 132nd annual meeting. UICC. 2004;21(25):35-6.
Dey S, Hablas A, Seifeldin IA, Ismail K, Ramadan M, El‐Hamzawy H, et al. Urban–rural differences of gynaecological malignancies in Egypt (1999-2002). BJOG. 2010;117(3):348-55.
Minelli L, Stracci F, Cassetti T, Canosa A, Scheibel M, Sapia IE, et al. Urban-rural differences in gynaecological cancer occurrence in a central region of Italy: 1978-1982 and 1998-2002. Europ J Gynaecol Oncol. 2007;28(6):468-72.
Sassone AM, Timor-Tritsch IE, Artner A, Westhoff C, Warren WB. Transvaginal sonographic characterization of ovarian disease: evaluation of a new scoring system to predict ovarian malignancy. Obstet Gynecol. 1991;78(1):70-6.
Narod SA, Sun P, Ghadirian P, Lynch H, Isaacs C, Garber J, et al. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet. 2001;357(9267):1467-70.
Curtin NJ. The United Irishmen: Popular Politics in Ulster and Dublin, 1791-1798. Oxford University Press, USA; 1994.
Maggino T, Gadducci A, D'addario V, Pecorelli S, Lissoni A, Stella M, et al. Prospective multicenter study on CA 125 in postmenopausal pelvic masses. Gynecol Oncol. 1994;54(2):117-23.
Tworoger SS, Fairfield KM, Colditz GA, Rosner BA, Hankinson SE. Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. Am J Epidemiol. 2007;166(8):894-901.
DiSilvestro P, Peipert JF, Hogan JW, Granai CO. Prognostic value of clinical variables in ovarian cancer. J Clin Epidemiol. 1997;50(5):501-5.
Mostafa MF, El-etreby N, Awad N. Retrospective analysis evaluating ovarian cancer cases presented at the clinical oncology department, Alexandria University. Alexandria J Med. 2012;48(4):353-60.
Singh PR, Arunachalam IL, Tan BY, Tock EP, Ratnam SS. Ovarian cancer in Oriental women from Singapore: disease pattern and survival. Int Surg. 1990;75(2):115-22.
Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol. 1998;69(2):103-8.
Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20(5):1248-59.
Sarwar CM, Siddiqui N, Khokhar RA, Badar F. Epithelial ovarian cancer at a cancer hospital in a developing country. Asian Pac J Cancer Prev. 2006;7(4):595-8.
Downloads
Published
How to Cite
Issue
Section
